Albany, US – DelveInsight launched its new report on Cushing’s Syndrome – Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “Cushing’s Syndrome – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cushing’s Syndrome, historical and forecasted epidemiology as well as the Cushing’s Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The key facts of the report:1. The endogenous prevalence of Cushing’s Syndrome is 1/26,000.2. Cushing’s syndrome most commonly affects adults between the ages of 25 to 40.3. Cushing’s disease prevalence maybe 5 to 25 per million per year.4. In the United States, the prevalence was higher than previously reported in European studies as it was found to affect 6.2 to 7.6 per million person-years.
Key benefits of the report:1. Cushing’s Syndrome market report covers a descriptive overview and comprehensive insight of the Cushing’s Syndrome epidemiology and Cushing’s Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Cushing’s Syndrome market report provides insights into current and emerging therapies.3. Cushing’s Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Cushing’s Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and leading the Cushing’s Syndrome market.
Request for sample pages: https://www.delveinsight.com/sample-request/cushings-syndrome-market
Cushing’s Syndrome (CS), also known as hypercortisolism, is a rare disorder, which refers to the clinical manifestations induced by chronic exposure to excess glucocorticoids and may have exogenous or endogenous origin.
“Cushing’s syndrome is at least three times more prevalent in women than in men, and mainly observed during the fourth to sixth decades of life.”
The key pharma players in Cushing’s syndrome market are:1. Recordati2. Corcept Therapeutics3. Strongbridge Biopharma4. HRA Pharma5. Millendo TherapeuticsAnd many others
Drugs covered:1. Osilodrostat2. Relacorilant3. Levoketoconazole4. Metyrapone5. ATR-101And many others
Download free sample report @https://www.delveinsight.com/sample-request/cushings-syndrome-market
Table of contents1. Report Introduction2. Cushing’s Syndrome Market Overview at a Glance3. Cushing’s Syndrome Disease Background and Overview4. Cushing’s Syndrome Epidemiology and Patient Population5. Cushing’s Syndrome Country- Wise Epidemiology5.1. United States5.2. EU-55.2.1. Assumptions and Rationale5.2.2. Germany5.2.3. France5.2.4. Italy5.2.5. Spain5.2.6. United Kingdom5.2.7. Japan6. Cushing’s Syndrome Treatments & Medical Practices7. Cushing’s Syndrome Marketed Products7.1. Mifepristone (Korlym): Corcept Therapeutics7.2. Pasireotide (Signifor): Recordati8. Cushing’s Syndrome Emerging Therapies8.1. Key Cross Competition8.2. Osilodrostat: Recordati8.3. Relacorilant: Corcept Therapeutics9. Cushing’s Syndrome Market Size10. 7MM: Country-Wise Market Analysis10.1. United States Market Size10.2. Germany Market Size10.3. France Market Size10.4. United Kingdom Market Size10.5. Spain Market Size10.6. Italy Market Size10.7. Japan Market Size11. Market Drivers12. Market Barriers13. Cushing’s Syndrome Report Methodology14. DelveInsight Capabilities15. Disclaimer16. About DelveInsight
Related reports:
Cushing’s Syndrome – Epidemiology Forecast to 2030
Cushing’s Syndrome Pipeline Insight, 2020
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/